CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

Clinical Pharmacology and Therapeutics
Matthias SchwabGerhard Treiber

Abstract

Proton pump inhibitors, metabolized by the polymorphic enzyme cytochrome P450 (CYP) 2C19, are essential drugs for Helicobacter pylori eradication. It was reported that patients with CYP2C19 wild type in Asia had lower eradication rates. This study tests the hypothesis that CYP2C19 wild type ( wt/wt ) in white patients is also associated with a higher probability of treatment failure. This was a cohort study involving 131 H pylori -positive white (German) patients treated by quadruple therapy including lansoprazole (30 mg twice daily for 5 days). Eradication success, as well as lansoprazole trough steady-state serum concentrations, was determined according to different CYP2C19 genotypes. We found 3 homozygous variant patients (2.3%) ( mt/mt, CYP2C19*2/*2 ), 42 heterozygous patients (32.1%) ( wt/mt, CYP2C19*1/*2 ), and 86 wild-type individuals (65.6%). Significant differences in eradication success could be found between wt/wt patients (80.2%) versus combined mt/mt (100%) and wt/mt patients (97.8%) ( P <.01; odds ratio, 10.8 [confidence interval, 1.4-84]), which were associated with corresponding changes in the serum levels of lansoprazole (median, 753 ng/mL for mt/mt, 59 ng/mL for wt/mt, and 21 ng/mL for wt/wt; P <.001). Apart f...Continue Reading

Associated Clinical Trials

Sep 11, 2015·Ping-I (William) Hsu, M.D.

Citations

May 1, 2008·Nature Clinical Practice. Gastroenterology & Hepatology·David Y Graham, Akiko Shiotani
Feb 9, 2012·Nature Reviews. Gastroenterology & Hepatology·Michael Camilleri
Jul 30, 2009·European Heart Journal·Céline VerstuyftRichard B Kim
Feb 5, 2009·The Journal of Antimicrobial Chemotherapy·Nicole WueppenhorstErik Glocker
Aug 18, 2005·Journal of Gastroenterology and Hepatology·Ulrich KlotzMatthias Schwab
Dec 20, 2005·Journal of Gastroenterology and Hepatology·P W Y LimB C Y Wong
Jan 18, 2006·Annual Review of Medicine·Michel EichelbaumWilliam E Evans
Jun 1, 2012·Clinical and Experimental Gastroenterology·Mitsushige Sugimoto, Takahisa Furuta
Jun 23, 2011·Pharmacogenomics·Krisztina HagymásiZsolt Tulassay
Jun 18, 2009·World Journal of Gastroenterology : WJG·Giovanni TarantinoDomenico Capone
Feb 23, 2013·World Journal of Gastroenterology : WJG·Hai-Jun Ma, Jin-Liang Wang
May 17, 2014·World Journal of Gastroenterology : WJG·Giovanni CammarotaAntonio Gasbarrini
Oct 11, 2014·Pharmacogenomics·John J Lima, James P Franciosi
Oct 4, 2006·Alimentary Pharmacology & Therapeutics·G Treiber, P Malfertheiner
Apr 26, 2008·European Journal of Clinical Investigation·P I HsuK H Lai
Oct 6, 2006·Expert Opinion on Pharmacotherapy·Yuri A Saito, Michael Camilleri
Jul 13, 2004·Basic & Clinical Pharmacology & Toxicology·Ulrich KlotzGerhard Treiber
Jan 12, 2007·Clinical Pharmacology and Therapeutics·T FurutaA Hishida
Jun 13, 2012·Journal of Pharmacy Practice·Joseph D MaGrace M Kuo
Apr 6, 2018·Expert Opinion on Drug Metabolism & Toxicology·Nihal El RoubyJulie A Johnson
Jun 25, 2009·The American Journal of Gastroenterology·Yuri A Saito, Nicholas J Talley
Jun 6, 2007·The Pharmacogenomics Journal·D Tomalik-ScharteJ Kirchheiner
Apr 26, 2015·The Kaohsiung Journal of Medical Sciences·Wen-Hung HsuChao-Hung Kuo
Dec 14, 2007·Clinical Pharmacokinetics·Kwong Ming FockEdmund Jon Deon Lee
May 2, 2009·Journal of Clinical Gastroenterology·Ping-Huei TsengMing-Shiang Wu
Feb 5, 2010·Journal of Thrombosis and Haemostasis : JTH·C S ZuernT Geisler
Jun 30, 2010·Drugs & Aging·Alberto PilottoDaniele Sancarlo
Aug 13, 2008·Analytical and Bioanalytical Chemistry·Ulrich M ZangerMatthias Schwab
Aug 6, 2008·European Journal of Clinical Pharmacology·Shaojun Shi, Ulrich Klotz
Feb 26, 2013·European Journal of Clinical Pharmacology·Satoshi YamadaTsukasa Uno
Jul 13, 2011·Alimentary Pharmacology & Therapeutics·J P Gisbert, X Calvet
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Jan 15, 2020·Current Drug Metabolism·Basu Dev BanerjeeTusha Sharma

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.